Skip to main content
Psychedex

25I-NBOMe

4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine

1Provenance card

the boundary, as counts

Sources

3327 with DOI

2 strong · 20 moderate · 10 weak · 1 unrated

Compilations

12026-04-25T22:53:33.199Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

44last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:29:13.724Z

notice · info card · emergency

Searches

191 with no results

queries and counts on the build

Claims checked

10271 supported

71 supported · 31 not

Correspondence

0received

consent field ships in Phase 4

Edges

316

derivations recorded for this entity

Complete over 33 sources, 1 compilation, and 44 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/25i-nbome/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-19issueIssued notice
  4. 2026-09-24srcCharacterization of the hepatic cytochrome P450 enzymes involved in the metabolism of 25I-NBOMe and 25I-NBOH
  5. 2026-09-24srcPharmacology and Toxicology of N-Benzylphenethylamine (NBOMe) Hallucinogens
  6. 2026-09-24srcOff-target activity of NBOMes and NBOMe analogs at the µ opioid receptor
  7. 2026-09-24srcStudies on the metabolism and toxicological detection of 25I-NBOMe in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS
  8. 2026-09-24srcHallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats
  9. 2026-09-24srcNeurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats.
  10. 2026-09-24srcPostmortem detection of 25I-NBOMe in fluids and tissues determined by HPLC-MS/MS from a traumatic death
  11. 2026-09-24src25I-NBOMe related death in Australia: a case report
  12. 2026-09-24srcA fatal poisoning involving 25C-NBOMe.
  13. 2026-09-24srcIs LSD toxic?
  14. 2026-09-24srcEffects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response
  15. 2026-09-24srcComparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats
  16. 2026-09-24srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
  17. 2026-09-24srcClinical and Toxicological Profile of NBOMes: A Systematic Review
  18. 2026-09-24srcHuman cytochrome P450 kinetic studies on six NBOMe-derived new psychoactive substances using the substrate depletion approach
  19. 2026-09-24srcTolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
  20. 2026-09-24srcN-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues
  21. 2026-09-24srcIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
  22. 2026-09-24srcNeurotoxicological profile of the hallucinogenic compound 25I-NBOMe
  23. 2026-09-24srcFatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014.
  24. 2026-09-24srcAnalysis of 25I-NBOMe, 25B-NBOMe, 25C-NBOMe and Other Dimethoxyphenyl-N-[(2-Methoxyphenyl)Methyl]Ethanamine Derivatives on Blotter Paper.
  25. 2026-09-24srcIdentification of Metabolite Biomarkers of the Designer Hallucinogen 25I-NBOMe in Mouse Hepatic Microsomal Preparations and Human Urine Samples
  26. 2026-09-24srcA Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State
  27. 2026-09-24srcPathological findings in 2 cases of fatal 25I-NBOMe toxicity
  28. 2026-09-24srcRadiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET.
  29. 2026-09-24srcPrevalence of use and acute toxicity associated with the use of NBOMe drugs
  30. 2026-09-24srcNBOMes-Highly Potent and Toxic Alternatives of LSD
  31. 2026-09-24srcMechanism of tolerance development to 2,5-dimethoxy-4-iodoamphetamine in rats: down-regulation of the 5-HT2A, but not 5-HT2C, receptor
  32. 2026-09-24srcSchedules of Controlled Substances: Temporary Placement of Three Synthetic Phenethylamines Into Schedule I
  33. 2026-09-24src25I-NBOMe CAS, Physical Properties
  34. 2026-09-24srcSchedules of Controlled Substances: Placement of Three Synthetic Phenethylamines Into Schedule I (Permanent)
  35. 2026-09-24src25I-NBOMe Legal Status
  36. 2026-09-24src25I-NBOMe: The first synthesis, history, and emergence on recreational market
  37. 2026-09-04issueIssued emergency
  38. 2026-09-04issueIssued info_card
  39. 2026-09-04issueIssued notice
  40. 2026-06-04proposal42 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  41. 2026-06-04publicationPublication — backfill
  42. 2026-04-25revisionRevision 1
  43. 2026-04-25absenceSearched ClinicalTrials.gov for "25I-NBOMe NBOMe hallucinogen" — no results
  44. 2026-04-25genGeneration — pipeline-v5pipeline-v5
  45. 2026-04-25rungeneration run

The same entries, as forms: six forms.